Esperion Therapeutics, Inc. (ESPR) research

Esperion Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$3.18
As of

Esperion Therapeutics, Inc. (ESPR): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-13.

As of . Source: SEC EDGAR filings for ESPR. Method and limitations.

SHARE THIS CARD

Share the ESPR intelligence card

A branded snapshot of ESPR: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ESPR intelligence card preview
Post to X
LIVE TERMINAL

See ESPR live in the terminal

Track ESPR's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live ESPR terminal, free

Active signals for ESPR

FREE, NO ACCOUNT

Every signal on ESPR, as it fires

You are seeing 5 of 19 signals recorded on ESPR since 2026-05-30.

The five above all landed on 2026-09-06. The other 14 were recorded on 2 other days. 15 of the 19 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ESPR (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 29664W105 · 2026Q2$22.5M0.02%,
MILLENNIUM MANAGEMENT LLCCUSIP 29664W105 · 2026Q2$7M0.00%,
SOROS FUND MANAGEMENT LLCCUSIP 29664W105 · 2026Q2$2.4M0.03%,
CITADEL ADVISORS LLCCUSIP 29664W105 · 2026Q2$1.5M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 29664W105 · 2026Q2$506K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ESPR

ESPR against its peers

ESPR's operating margin of 15.0% ranks in the 64th percentile of 17 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricESPRPeer medianPercentilen
Revenue FY403M USD411M USD4819
Gross marginn/a56.3%n/a6
Operating margin15.0%8.5%6417
Net margin-5.6%1.2%3418
Return on equityn/a-6.5%n/a22
P / En/a14.0xn/a10

Peers (24): ACRS, COLL, PCRX, AMPH, ALMS, ANRO, PAHC, INVA, OMER, AVIR, XERS, ANIP, BIOA, NUVB, TRVI, BHC, OCUL, NKTR, FULC, SUPN, HRMY, GPCR, SIGA, OGN. Left out: ACB (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ESPR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more ESPR signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ESPRand get the insider, 13F, options, and confluence read in one view.

Open the live ESPR terminal, free